NexImmune, Inc.

NexImmune is a publicly traded, clinical stage biotechnology company developing unique approaches to T cell immunotherapies based on its propriety Artificial Immune Modulation (AIM™) technology. NexImmune has a differentiated platform and pipeline of product candidates in pre-clinical and phase 1/2 stages with lead programs focused on the treatment of relapsed acute myeloid leukemia (AML) after allogenic stem cell transplantation and multiple myeloma refractory to >3 prior lines of therapy. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. By mimicking natural T cell biology, NexImmune’s T cell product candidates are designed to combine the attributes of cellular precision, potency, and persistence with reduced potential for undesired toxicities. For the last decade, the AIM platform has evolved into a stable platform for various therapy targets providing an opportunity to make a massive impact due to its adaptability and flexibility in oncology, autoimmune disorders, infectious disease, and beyond.